RE:RE:RE:RE:RE:RE:RE:RE:RE:Well...Not too sure the Q4 numbers will be good or not, or whether they bring in someone before then or not. Really, if the Q4 numbers are poor, new CEO just blames old CEO akin to new head of state blaming the last head of state for the garbage they inherited so I don't think we can say the Q4 numbers will be more or less shytey simply because of that.
Either way, who they bring in will be tell-tale. If our BoD big guns can convince some big shot Pharma or Drug chain executive to come in, we'll do very well. Next year will certainly be the turnaround year if one is to exist. International deals and movement ought to start coming online and that will either make or break.....and I say this as someone who is a bag holder wanting 'make'....
Lemoyne wrote: Look, this is speculation, but IMO, I think they timed the CEO change because they know Q4 is decent, at least part of them, (ie white label growth) and they want to turn the page with new high management on the getgo for what would be a break out year in 2021. I doubt they would sack Pat to have the new CEO start off with bad news in Q4, it wouldn't make sense to have new CEO put on the chopping block right off the bat. If bad news were coming in Q4 they'd let Pat eat dirt and sack him afterwards, giving the first good news to new CEO.
I also doubt they'd be able to recruit high level CEO with a bad news start.
Whatever this opinion is worth, I've been wrong before.